Zentalis Pharmaceuticals (ZNTL)
NASDAQ:ZNTL
ZNTL Stock Chart & Stats
$1.41
-$0.17(-5.69%)
At close: 4:00 PM EST
$1.41
-$0.17(-5.69%)
Day’s Range― - ―
52-Week Range$1.01 - $3.95
Previous CloseN/A
Volume750.15K
Average Volume (3M)716.92K
Market Cap
$195.77M
Enterprise Value$199.35M
Total Cash (Recent Filing)$245.89M
Total Debt (Recent Filing)$39.58M
Price to Earnings (P/E)―
Beta2.68
Next Earnings
May 13, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding70,931,015
10 Day Avg. Volume819,524
30 Day Avg. Volume716,917
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.77
Enterprise Value/Market Cap1.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-475.78
Enterprise Value/Ebitda-1.46
Forecast
1Y Price Target
$7.25Price Target Upside414.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.86
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyConsistent tumor responses with azenosertib in heavily treated Cyclin E1‑positive ovarian cancer patients indicate a meaningful clinical benefit relative to standard chemotherapy and support future approval prospects.
Program ExpansionMultiple ongoing development programs, including a Phase 1 combination trial in ovarian cancer, broaden the therapeutic pathway for azenosertib and increase the likelihood of clinically relevant outcomes.
Safety ProfileAzenosertib has demonstrated a manageable safety profile across trials, suggesting tolerability advantages that could help patient acceptance compared with traditional chemotherapy.
Bears Say
Diagnostic Integration RiskUncertainty about integrating the Cyclin E1 IHC diagnostic into routine clinical practice creates execution risk in identifying and enrolling the intended patient population.
Dose Selection RiskUncertainty about which dosing regimen will be chosen for registrational studies creates execution risk that could complicate dose confirmation and trial progression.
Regulatory And Outcome DependenceDependence on pivotal trial results and subsequent regulatory review means unfavorable outcomes or delays could materially weaken the stock outlook.
Zentalis Pharmaceuticals News
ZNTL FAQ
What was Zentalis Pharmaceuticals’s price range in the past 12 months?
Zentalis Pharmaceuticals lowest stock price was $1.01 and its highest was $3.95 in the past 12 months.
What is Zentalis Pharmaceuticals’s market cap?
Zentalis Pharmaceuticals’s market cap is $195.77M.
When is Zentalis Pharmaceuticals’s upcoming earnings report date?
Zentalis Pharmaceuticals’s upcoming earnings report date is May 13, 2026 which is in 34 days.
How were Zentalis Pharmaceuticals’s earnings last quarter?
Zentalis Pharmaceuticals released its earnings results on Mar 26, 2026. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.427 by -$0.073.
Is Zentalis Pharmaceuticals overvalued?
According to Wall Street analysts Zentalis Pharmaceuticals’s price is currently Undervalued.
Does Zentalis Pharmaceuticals pay dividends?
Zentalis Pharmaceuticals does not currently pay dividends.
What is Zentalis Pharmaceuticals’s EPS estimate?
Zentalis Pharmaceuticals’s EPS estimate is -0.5.
How many shares outstanding does Zentalis Pharmaceuticals have?
Zentalis Pharmaceuticals has 70,931,015 shares outstanding.
What happened to Zentalis Pharmaceuticals’s price movement after its last earnings report?
Zentalis Pharmaceuticals reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.427. Following the earnings report the stock price went down -21.348%.
Which hedge fund is a major shareholder of Zentalis Pharmaceuticals?
Currently, no hedge funds are holding shares in ZNTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentalis Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.25 (414.18% Upside)
$7.25 (414.18% Upside)
Hedge Fund Trend
Decreased
By 14.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $7.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.33%
12-Months-Change
Fundamentals
Return on Equity
-52.77%
Trailing 12-Months
Asset Growth
-32.85%
Trailing 12-Months
Company Description
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals (ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The company operates in the biotechnology sector, leveraging its expertise in medicinal chemistry and translational science to develop drug candidates aimed at improving patient outcomes in oncology. Zentalis' core products include a pipeline of proprietary agents designed to address unmet medical needs in cancer treatment.
ZNTL Stock 12 Month Forecast
Average Price Target
$7.25
▲(414.18% Upside)
Technical Analysis
MacroGenics
―
VistaGen Therapeutics
―
Anixa Biosciences
―
Spero Therapeutics
―
Surrozen
―
Ownership Overview
29.49% Insiders
5.81% Mutual Funds
18.34% Other Institutional Investors
42.00% Public Companies and
Individual Investors